Methods and compositions relating to anti-PD1 antibody reagents

Patent metadata

Field	Value
Publication number	US-11427636-B2
Application number	US-201816608275-A
Country	US
Kind code	B2
Filing date	May 1, 2018
Priority date	May 1, 2017
Publication date	Aug 30, 2022
Grant date	Aug 30, 2022

Abstract

Described herein are novel anti-PD1 antibody reagents (e.g., antibodies, antigen-binding fragments thereof, and/or chimeric antigen receptors). Also described herein antibody-drug conjugates or kits comprising the disclosed antibody reagents, as well as methods of treating cancer by administering the disclosed antibody reagents.

First claim

What is claimed herein is:

1. An antibody, antibody reagent, antigen-binding fragment thereof, or chimaeric antigen receptor (CAR), that specifically binds an PD1 polypeptide, said antibody reagent, antigen-binding portion thereof, or CAR comprising:
heavy chain CDRs having the amino acid sequences of SEQ ID NOs: 23-25 and light chain CDRs having the amino acid sequences of SEQ ID NOs: 26-28; or
heavy chain CDRs having the amino acid sequences of SEQ ID NOs: 29-31 and light chain CDRs having the amino acid sequences of SEQ ID NOs: 32-34; or
heavy chain CDRs having the amino acid sequences of SEQ ID NOs: 35-37 and light chain CDRs having the amino acid sequences of SEQ ID NOs: 38-40; or
heavy chain CDRs having the amino acid sequences of SEQ ID NOs: 41-43 and light chain CDRs having the amino acid sequences of SEQ ID NOs: 44-46; or
heavy chain CDRs having the amino acid sequences of SEQ ID NOs: 47-49 and light chain CDRs having the amino acid sequences of SEQ ID NOs: 50-52; or
heavy chain CDRs having the amino acid sequences of SEQ ID NOs: 53-55 and light chain CDRs having the amino acid sequences of SEQ ID NOs: 56-58; or
heavy chain CDRs having the amino acid sequences of SEQ ID NOs: 59-61 and light chain CDRs having the amino acid sequences of SEQ ID NOs: 62-64; or
heavy chain CDRs having the amino acid sequences of SEQ ID NOs: 65-67 and light chain CDRs having the amino acid sequences of SEQ ID NOs: 68-70; or
heavy chain CDRs having the amino acid sequences of SEQ ID NOs: 71-73 and light chain CDRs having the amino acid sequences of SEQ ID NOs: 74-76; or
heavy chain CDRs having the amino acid sequences of SEQ ID NOs: 77-79 and light chain CDRs having the amino acid sequences of SEQ ID NOs: 80-82; or
heavy chain CDRs having the amino acid sequences of SEQ ID NOs: 83-85 and light chain CDRs having the amino acid sequences of SEQ ID NOs: 86-88.

2. The antibody, antibody reagent, antigen-binding portion thereof, or CAR of claim 1 , comprising the heavy chain sequence of any of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19 or 21.

3. The antibody, antibody reagent, antigen-binding portion thereof, or CAR of claim 1 , comprising the light chain sequence of any of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, or 22.

4. The antibody, antibody reagent, antigen-binding portion thereof, or CAR of claim 1 , comprising:
the heavy chain sequence of SEQ ID NO: 1 and the light chain sequence of SEQ ID NO: 2; or
the heavy chain sequence of SEQ ID NO: 3 and the light chain sequence of SEQ ID NO: 4; or
the heavy chain sequence of SEQ ID NO: 5 and the light chain sequence of SEQ ID NO: 6; or
the heavy chain sequence of SEQ ID NO: 7 and the light chain sequence of SEQ ID NO: 8; or
the heavy chain sequence of SEQ ID NO: 9 and the light chain sequence of SEQ ID NO: 10; or
the heavy chain sequence of SEQ ID NO: 11 and the light chain sequence of SEQ ID NO: 12; or
the heavy chain sequence of SEQ ID NO: 13 and the light chain sequence of SEQ ID NO: 14; or
the heavy chain sequence of SEQ ID NO: 15 and the light chain sequence of SEQ ID NO: 16; or
the heavy chain sequence of SEQ ID NO: 17 and the light chain sequence of SEQ ID NO: 18; or
the heavy chain sequence of SEQ ID NO: 19 and the light chain sequence of SEQ ID NO: 20; or
the heavy chain sequence of SEQ ID NO: 21 and the light chain sequence of SEQ ID NO: 22.

5. The antibody, antibody reagent, antigen-binding portion thereof, or CAR of claim 4 , further comprising a conservative substitution in a sequence not comprised by a CDR.

6. The antibody, antibody reagent, antigen-binding portion thereof, or CAR of claim 1 , wherein the antibody reagent or antigen-binding fragment thereof is fully human or fully humanized.

7. The antibody, antibody reagent, antigen-binding portion thereof, or CAR of claim 1 , wherein the antibody reagent or antigen-binding fragment thereof is fully humanized except for the CDR sequences.

8. The antibody, antibody reagent, antigen-binding portion thereof, or CAR of claim 1 , wherein the reagent or fragment is selected from the group consisting of:
an immunoglobulin molecule, a monoclonal antibody, a chimeric antibody, a CDR-grafted antibody, a humanized antibody, a Fab, a Fab′, a F(ab′)2, a Fv, a disulfide linked Fv, a scFv, a single domain antibody, a diabody, a multispecific antibody, a dual specific antibody, an anti-idiotypic antibody, and a bispecific antibody.

9. A composition comprising the antibody, antibody reagent, antigen-binding portion thereof, or CAR of claim 1 , and a chemotherapeutic agent.

10. The composition of claim 9 , wherein the antibody, antibody reagent, antigen-binding portion thereof, or CAR is conjugated to the chemotherapeutic agent.

11. A method of treating cancer in a subject in need thereof, the method comprising administering the antibody, antibody reagent, antigen-binding fragment thereof, or CAR of claim 1 to the subject.

12. The method of claim 11 , wherein the cancer is selected from the group consisting of:
Non-small cell lung cancer; melanoma; metastatic melanoma; renal cell carcinoma; squamous cell carcinoma of the head and neck; Hodgkin lymphoma; classical Hodgkin lymphoma; and urothelial carcinoma.

Assignees

• Childrens Medical Ct Corp

Inventors

• Alt Frederick W
• Tian Ming
• Cheng Hwei-Ling

Classifications

• G01N33/5759

  involving compounds localised on the membrane of tumour or cancer cells · CPC title

• G01N33/5751

  of the skin, e.g. melanoma · CPC title

• G01N33/57505

  of the blood, e.g. leukaemia · CPC title

• G01N33/57525 Primary

  of the liver or pancreas · CPC title

• A61P35/00

  Antineoplastic agents · CPC title